Ankrin Therapeutics ApS: Financial statements 2021
CVR: 39788705
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
Ankrin Therapeutics ApS (CVR 39788705) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -2,427,405 and a net result of DKK -4,493,439 compared with DKK -3,485,420 the year before. Equity in the 2021 report amounted to DKK -1,712,318. The company had 3 employees in the financial year.
- Gross Profit
- DKK -2,427,405
- Profit/Loss
- DKK -4,493,439
- Equity
- DKK -1,712,318
- Total Assets
- DKK 6,578,795
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | -2.4 mio. | -4.5 mio. | -1.7 mio. | 3 |
| 2020 | - | -2.1 mio. | -3.5 mio. | 2.8 mio. | 2 |
Official annual report
Find more companies like Ankrin Therapeutics ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
Ankrin Therapeutics ApS has published its annual report for 2020. Gross profit came to DKK -2,066,728, and the net result was DKK -3,485,420.
As of February 15, 2021, Ulrik Svane Sørensen has joined the board of directors of Ankrin Therapeutics ApS.
As of February 15, 2021, Thomas Michael Frimurer has left the board of directors of Ankrin Therapeutics ApS.
As of February 15, 2021, Jimmy Arnold Van heusden is registered as chairman of Ankrin Therapeutics ApS.
As of February 14, 2021, Ulrik Svane Sørensen has stepped down as chairman of Ankrin Therapeutics ApS.
About Ankrin Therapeutics ApS
Ankrin Therapeutics ApS was a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2018. The company has been dissolved on 5 December 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Ankrin Therapeutics IvS. The company has 4 employees (2024). In 2023, the company reported a gross profit of DKK -497,960 and a net result of DKK -2,334,458 compared with DKK -2,732,702 the year before. Equity in the 2023 report amounted to DKK -6,779,478.